An observational study in Heart Failure, sponsored by Impulse Dynamics. Recruiting at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Impulse Dynamics · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Heart Failure by Impulse Dynamics — 4 open to participants now, 6 under way, none of them phase 3. Heart Failure · Impulse Dynamics.
Among the 11 studies in Heart Failure by Impulse Dynamics, this one is one of 3 that started in 2025, is one of 4 observational ones, and was the 10th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →4 of the 11 studies in Heart Failure by Impulse Dynamics are open now, in 2 countries. Recruiting first, the newest first:
Impulse Dynamics · Sites in United States
Ages 18+
Impulse Dynamics · Sites in Italy
Ages 18+
Impulse Dynamics · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 5,500 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 160 across the 7 interventional studies, 2,410 across the 4 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Impulse Dynamics is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
1 of the studies in Heart Failure by Impulse Dynamics that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06580392Impulse DynamicsCCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Heart Failure by Impulse Dynamics, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.
This is a global, prospective and retrospective, multicenter, single-arm, observational study intended to include patients who will receive/have received CCM therapy with an Impulse Dynamics system, including future CCM technologies (e.g. CCM-D), for a follow-up period of at least 5 years.
Patients who will receive/have received CCM therapy with an Impulse Dynamics system
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prospective Cohort
Patients who will receive/ have received CCM therapy with an Impulse Dynamics devices
Patients who will receive CCM therapy with an Impulse Dynamics devices
Assess CCM's effect on the rate and length of stay of heart failure (HF) hospitalizations
Change in the HF hospitalization / urgent HF visit rate and hospital length of stay from 1 year prior to 1 year following index implantation.
Time frame: 1 Year
Demonstrate the long-term safety of CCM therapy in a real-world setting, by assessing the rate of device- or procedure-related complications.
Rate of freedom from a composite of device- or procedure-related complication post-index implantation procedure. Serious procedure related complications occurring through the end of 30 days following the index procedure. Serious CCM device-related complications\* occurring through the end of 1-year following the index procedure. \* excluding lead-related complications
Time frame: 5 Years
Assess CCM's effect on clinical outcomes
Composite of all-cause mortality, heart-failure hospitalizations/urgent heart failure visits, progression to LVAD/heart transplant 1-, 3-, and 5-years following the index procedure.
Time frame: 5 Years
Assess CCM's effect on mortality (all-cause, cardiovascular, and heart failure related)
All-cause: Observed mortality will be compared to predicted mortality for the subject group according to the Seattle Heart Failure Model (SHFM) and/or Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) at 1-, 3-, and 5-years following the index procedure. Cardiovascular related mortality will be assessed at 1-, 3-, and 5-years following the index procedure.
Time frame: 5 Year
Assess CCM's effect on healthy days at home (HDAH)
Assessment of HDAH 1 year prior to 3 years following index implantation.
Time frame: 3 Years
Assess CCM's effect on functional capacity
Change in NYHA Functional Class from baseline to 1-, 2-, 3-, 4-, and 5-years following the index procedure. Change in 6-minute walk test (6MWT) from baseline to 1 year following the index procedure.
Time frame: 5 Year
Kansas City Cardiomyopathy Questionnaire (KCCQ)
Change in KCCQ score from baseline to 6 months and 1 year after the index procedure. Scores range from 0 to 100, with higher scores showing better health status and lower scores showing worsen health status.
Time frame: 1 Year
Assess CCM's effect cardiovascular reverse remodeling
Change in LVEF, LVESV, LVEDV from baseline to 1-, 2-, 3-, 4-, and 5-years following the index procedure.
Time frame: 5 Year
Assess CCM's effect QRS duration
Change in QRS duration from baseline to 1-, 2-, 3-, 4-, and 5-years following the index procedure.
Time frame: 5 Years
Assess CCM's systemic effects
Change in eGFR and BNP from baseline to 1-, 2-, 3-, 4-, and 5-years following the index procedure.
Time frame: 5 Years
Assess long-term CCM device-related adverse events and lead related events
An assessment of the incidence of CCM device-related serious complications and non-serious CCM-device-related observations occurring during the 5-year period following the index procedure.
Time frame: 5 Years
Assess the dose response of CCM therapy
Correlation of CCM % and milliamp (mA) delivered with clinical outcomes and health status
Time frame: 5 Year
Evaluate subject battery charging compliance
Assess overall battery charging compliance defined as 60 minutes of charging per 10-day period between charging sessions (Expressed as percentage of compliant charging periods per subject over time e.g., number of compliant charging cycles ÷ total expected cycles × 100%).
Time frame: 5 Year
Assess the effect of ancillary equipment on clinical outcomes
Impact of ancillary equipment on clinical outcomes at 1- 2-, 3-, 4-, and 5-years following the index procedure. Including but not limited to: Lead type: style-driven lead, lumenless lead Guiding sheath/catheter
Time frame: 5 Years
Assess CCM clinical outcomes by subject sub-groups
Assess CCM effectiveness at various timepoints in sub-groups of interest, including but not limited to: Male vs female \<65 vs ≥ 65-year-old Ischemic vs non-ischemic CRT non-responders Patients with concomitant devices (e.g. CRT, pacemaker, LBBP) Patients with wide, intermediate, narrow QRS Patients with cardiac amyloidosis
Time frame: 5 Years
Plan to share: No — The data are part of an ongoing commercial development program and are considered proprietary at this stage.
Started Nov 2025 (actual). Primary completion is estimated for Aug 2035, 117 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Impulse Dynamics